title: Daclizumab as escape therapy for late acute kidney rejection in the presence of FK506 nephrotoxicity.
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
authors.forename: F
authors.initials: F
authors.lastname: Triponez
authors.forename: P Y
authors.initials: PY
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Williamson
authors.forename: P
authors.initials: P
authors.lastname: Morel
mesh_terms: D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D016030:Kidney Transplantation; D008297:Male; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects*; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D016559:Tacrolimus